Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721221 | 0.94 | TACR2 (0.54) | FDPSAKR1C3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL9077155 | 0.94 | TACR2 (0.54) | FDPSAKR1C3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL5213944 | 0.94 | TACR2 (0.54) | FDPSAKR1C3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL4293136 | 0.93 | FDPS (0.54) | FDPSAKR1C3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL7141110 | 0.92 | FDPS (0.55) | FDPSAKR1C3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL30467215 | 0.92 | FDPS (0.55) | FDPSAKR1C3MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL6229249 | 0.91 | FDPS (0.63) | FDPSMAPTSMN1; SMN2NPSR1LMNA | |
| SCHEMBL9078005 | 0.91 | FDPS (0.72) | FDPSMAPTSMN1; SMN2NPSR1LMNA | |
| SCHEMBL31331562 | 0.91 | FDPS (0.72) | FDPSMAPTSMN1; SMN2NPSR1LMNA | |
| SCHEMBL21427194 | 0.91 | FDPS (0.54) | FDPSAKR1C3MAPTSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3828163-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | AUTOTAC INC (KR) | 2026-05-20 | — | — | EP | disclosed |
| EP-3828164-B1 | NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION COMPRISING SAME | AUTOTAC INC (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2025-09-30 | — | — | US | disclosed |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-3828162-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES COMPRISING THE SAME | AUTOTAC INC (KR) | 2025-07-09 | — | — | EP | disclosed |
| US-12129218-B2 | AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same | AUTOTAC INC. (KR) | 2024-10-29 | — | — | US | disclosed |
| US-12065394-B2 | Compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising thereof | Seoul National University R&DBFoundation (KR) | 2024-08-20 | — | — | US | disclosed |
| US-11981618-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2024-05-14 | — | — | US | disclosed |
| CN-112672993-B | Novel AUTOTAC chimeric compounds and compositions comprising same for preventing, ameliorating or treating diseases by targeted protein degradation | 奧土择破利悟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-112105598-B | Compounds for preventing or treating obesity or metabolic syndrome and pharmaceutical compositions comprising the same | 普罗泰克株式会社 | 2023-06-27 | — | — | CN | disclosed |
| WO-2019190172-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR METABOLIC SYNDROME COMPRISING SAME | 주식회사 프로텍바이오 | 2019-10-03 | — | — | WO | disclosed |
| CN-103764837-A | Yeast strain for the production of proteins with modified O-glycosylation | MERCK SHARP & DOHME | 2014-04-30 | — | — | CN | disclosed |
| EP-2678440-A2 | YEAST STRAIN FOR THE PRODUCTION OF PROTEINS WITH MODIFIED O-GLYCOSYLATION | Merck Sharp & Dohme Corp. (US) | 2014-01-01 | — | — | EP | disclosed |
| CN-101365783-B | Production of glycoproteins with reduced o-glycosylation | GLYCOFI INC | 2013-07-17 | — | — | CN | disclosed |
| WO-2012115903-A2 | YEAST STRAIN FOR THE PRODUCTION OF PROTEINS WITH MODIFIED O-GLYCOSYLATION | MERCK SHARP & DOHME CORP. (US) | 2012-08-30 | — | — | WO | disclosed |
| CN-101365783-A | Production of glycoproteins with reduced o-glycosylation | GLYCOFI INC (US) | 2009-02-11 | — | — | CN | disclosed |
| EP-1954815-A2 | PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION | Glycofi, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007061631-A2 | PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION | GLYCOFI, INC (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1313471-A1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | Oxford GlycoSciences (UK) Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002017915-A1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065394-B2 | Compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising thereof | GPR119, SLC5A1, FABP4 | FDPS 692/4885AKR1C3 222/4885MAPT 3565/4885 |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | FDPS 3038/4885AKR1C3 3116/4885MAPT 30/4885 |
| US-12129218-B2 | AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same | ATG7, SQSTM1, CTSA | FDPS 4116/4885AKR1C3 1344/4885MAPT 22/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | FDPS 4002/4885AKR1C3 4525/4885MAPT 240/4885 |
| US-11981618-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | FDPS 3173/4885AKR1C3 3210/4885MAPT 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.